About Cytokinetics, Incorporated
https://www.cytokinetics.comCytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.
CEO
Robert I. Blum
Compensation Summary
(Year 2016)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2013-06-25 | Reverse | 1:6 |
ETFs Holding This Stock
Summary
Showing Top 3 of 204
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Needham
Buy
Goldman Sachs
Buy
B. Riley Securities
Buy
Citigroup
Buy
Stifel
Buy
Grade Summary
Showing Top 6 of 17
Price Target
Institutional Ownership
T. ROWE PRICE INVESTMENT MANAGEMENT, INC.
Shares:19.08M
Value:$1.23B
BLACKROCK, INC.
Shares:15.53M
Value:$1B
BLACKROCK INC.
Shares:14.67M
Value:$947.86M
Summary
Showing Top 3 of 457
About Cytokinetics, Incorporated
https://www.cytokinetics.comCytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $1.94M ▼ | $166.01M ▼ | $-306.18M ▼ | -15.81K% ▼ | $-2.55 ▼ | $-277.18M ▼ |
| Q2-2025 | $66.77M ▲ | $175.99M ▲ | $-134.37M ▲ | -201.25% ▲ | $-1.12 ▲ | $-107.82M ▲ |
| Q1-2025 | $1.58M ▼ | $57.37M ▼ | $-161.38M ▼ | -10.22K% ▼ | $-1.36 ▼ | $-136.13M ▼ |
| Q4-2024 | $16.93M ▲ | $62.34M ▲ | $-150.02M ▲ | -886.28% ▲ | $-1.27 ▲ | $-125.04M ▲ |
| Q3-2024 | $463K | $56.65M | $-160.54M | -34.67K% | $-1.36 | $-135.84M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $962.53M ▲ | $1.44B ▲ | $1.96B ▲ | $-521.12M ▼ |
| Q2-2025 | $858.13M ▼ | $1.23B ▼ | $1.59B ▲ | $-368.72M ▼ |
| Q1-2025 | $938.22M ▼ | $1.26B ▼ | $1.53B ▼ | $-266.41M ▼ |
| Q4-2024 | $1.08B ▲ | $1.4B ▼ | $1.54B ▲ | $-135.37M ▼ |
| Q3-2024 | $1.01B | $1.44B | $1.45B | $-13.91M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-306.18M ▼ | $-107.5M ▲ | $-70.98M ▼ | $330.47M ▲ | $152.03M ▲ | $-116.86M ▲ |
| Q2-2025 | $-134.37M ▲ | $-128.24M ▲ | $52.88M ▼ | $78.53M ▲ | $2.5M ▲ | $-132.38M ▲ |
| Q1-2025 | $-161.38M ▼ | $-131.62M ▼ | $105.96M ▼ | $4.75M ▲ | $-21.18M ▼ | $-137.28M ▼ |
| Q4-2024 | $-150.02M ▲ | $-65.57M ▲ | $110.86M ▲ | $2.38M ▼ | $47.97M ▲ | $-66.86M ▲ |
| Q3-2024 | $-160.54M | $-101.5M | $-45.05M | $3.42M | $-143.25M | $-103.95M |
Revenue by Products
| Product | Q2-2024 | Q3-2024 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Collaboration Revenues | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Research And Development | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
Robert I. Blum
Compensation Summary
(Year 2016)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2013-06-25 | Reverse | 1:6 |
ETFs Holding This Stock
Summary
Showing Top 3 of 204
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Needham
Buy
Goldman Sachs
Buy
B. Riley Securities
Buy
Citigroup
Buy
Stifel
Buy
Grade Summary
Showing Top 6 of 17
Price Target
Institutional Ownership
T. ROWE PRICE INVESTMENT MANAGEMENT, INC.
Shares:19.08M
Value:$1.23B
BLACKROCK, INC.
Shares:15.53M
Value:$1B
BLACKROCK INC.
Shares:14.67M
Value:$947.86M
Summary
Showing Top 3 of 457